Skip to main content
. 2021 Feb 9;11:30. doi: 10.1186/s13613-021-00823-7

Table 2.

Primary and secondary outcomes

Non-invasive ventilation (n = 86) High-flow nasal oxygen alone (n = 64) Absolute difference % (95% CI) p value
Primary outcome
 Reintubation at day 7, n (%) 11 (13%) 17 (27%) − 14 (− 27 to − 1) 0.032
Secondary outcomes
 Post-extubation respiratory failure, n (%) 22 (26%) 23 (36%) − 10 (− 25 to 4) 0.171
 Use of NIV to treat post-extubation respiratory failure, n (%) 19/22 (86%) 6/23 (26%) 60 (32 to 76) < 0.001
 Reintubation at day 7 among patients with post-extubation respiratory failure, n (%) 10/22 (45%) 14/23 (61%) − 15 (− 40 to 13) 0.300
 Reintubation at 48 h, n (%) 7 (8%) 11 (17%) − 9 (− 21 to 2) 0.092
 Reintubation at 72 h, n (%) 8 (9%) 15 (23%) − 14 (− 27 to − 2) 0.018
 Reintubation in ICU, n (%) 11 (13%) 18 (28%) − 15 (− 28 to − 2) 0.019
 Length of stay in ICU, median (IQR), days 13 [8–21] 12 [8-19] 0.908
 Length of stay in hospital, median (IQR), days 26 [14–47] 23 [16–32] 0.406
 Mortality in ICU, n (%) 5 (6%) 6 (9%) − 4 (− 14 to 5) 0.408
 Mortality in hospital, n (%) 15 (17%) 8 (12%) 5 (− 7 to 16) 0.406

Italic means that there is a significant difference (p < 0.05)

NIV non-invasive ventilation, CI confidence interval, ICU intensive care unit, IQR interquartile range (25–75th percentiles)